The abstract is read at the publisher; the summary is JClub's.
Pathogenic SCN1A variants account for 95% of individuals with Dravet syndrome, with typical onset around 6 months and frequent seizures that often coincide with developmental slowing or regression.
- Why it matters: The condition has a poor prognosis and high mortality risk, and early recognition is needed to choose antiseizure medications and interpret outcomes of emerging therapies.
- What they did: The review synthesizes clinical features across the lifespan, molecular findings including de novo SCN1A variants and possible parental mosaicism, and evidence from natural history and therapeutic trials.
- The result: Newer antiseizure medications are linked to improved seizure control and sometimes developmental gains, while antisense oligonucleotide and genetic therapy trials show promise for transforming outcomes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.